AN2 Therapeutics director Robin Shane Readnour reports disposal of common shares worth $97,645.76
Reuters2026/09/08 23:43- AN2 Therapeutics director Robin Shane Readnour reported sales of common stock on Sept. 3 and Sept. 8.
- Total shares sold: 16,119; weighted average prices: $6.07 and $6.02.
- Indirect holdings stood at 562,715 shares and 630,644 shares after Sept. 3 transactions.
- Indirect holdings stood at 557,990 shares and 625,350 shares after Sept. 8 transactions.
- Readnour also reported 9,077 shares held directly.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Sasol agrees to sell Nitrates business to Enaex Africa, keeps 23% stake
The United States implements import bans on some Canadian products. Which US stocks are affected?
The United States has imposed tariffs on certain Canadian products, making these U.S. stocks worth watching.
Jing Rui Wang Pu (JRWP.US) makes another attempt to list on Nasdaq, raising the fundraising amount significantly to $31 million.
JRWP.US resubmitted its initial public offering (IPO) application to the U.S. Securities and Exchange Commission (SEC) on Tuesday.
Asiamet Resources LTIP Tranche 1 vests, converts 79.85 million performance rights into shares
Crypto prices
More
